Navigation Links
KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue

Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitors selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins.

Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinity provides critical information to select the right lead compound for clinical development.

KinAffinity combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitors quantitative cellular target profile. The inhibitors targets are ranked by their affinities and reported to the customer.

KinAffinity is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.


KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we closely cooperate with several of the Institutes most outstanding scientists in the field of chemical proteomics and quantitative mass spectrometry, namely Dr. Henrik Daub, Prof. Jesper Olsen and Dr. Jrgen Cox. KINAXOs technology portfolio delivers direct insights into a compounds cellular interactions and its mode of action and is routinely applied to decrease drug development times and improve therapeutic strategies. To expand its KinAffinity platform, KINAXO recently received financial funding from the Bavarian Ministry of Economics. The underlying technology was licensed from the Max Planck Society and co-developed by scientists of the Max Planck Institute of Biochemistry and KINAXOs scientists.
KINAXO has several ongoing collaborations with major pharmaceutical and biotechnology companies such as Boehringer Ingelheim, Johnson & Johnson and Bayer, and is financed by European investors BioM, High-Tech Grnderfonds, KfW, the Max Planck Society, and Mountain Partners.


Dr. Jutta Fritz
Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried, Germany
Phone +49 89 4613363-22

b3c newswire

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Springer launches SpringerImages
3. ESHRE launches international study of polar body screening
4. Nutricia launches Nutra Neocate, weaning product designed for cows’ milk protein allergy
5. Swiss Initiative in Systems Biology launches new projects
6. Springer launches
7. Springer launches
8. UC Davis launches One Health care for wild mountain gorillas and human neighbors
9. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
10. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
11. Iowa State chemist synthesizes carbohydrates, launches startup company
Post Your Comments:
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology: